Psychopharmacology and Psychiatry Updates
- Episodios
- 100
- Se publica
- cada semana
- Último episodio
- 12 Nov 2026
Sobre el podcast
Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.
Episodios 100
Liver Disease: Buprenorphine, Methadone, and Smoking Cessation Agents
Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Flavio Guzmán, M.D. Learn more about our memberships here Earn 1.25 CME: Addiction Psychopharmacology in Patients with Medical Comorbidities Liver Disease …
Notas del episodio
Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Flavio Guzmán, M.D.
Catatonia: Should Antipsychotics Always Be Avoided?
Faculty: Scott R. Beach, M.D. Host: Flavio Guzmán, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 88 Catatonia: Should Antipsychotics Always Be Avoided?
Prazosin for PTSD Nightmares
In this episode, we explore prazosin for PTSD-related nightmares with Dr. David Osser. He explains why prazosin stands out among alpha-1 blockers, which patients are most likely to respond, and why so many …
Notas del episodio
In this episode, we explore prazosin for PTSD-related nightmares with Dr. David Osser. He explains why prazosin stands out among alpha-1 blockers, which patients are most likely to respond, and why so many trials failed from underdosing, including how titration differs for men and women.
Faculty: David Osser, M.D. Host: Flavio Guzmán, M.D.
First-Episode Psychosis in Women
Faculty: Amanda Koire, M.D., Ph.D. Host: Flavio Guzmán, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 87 First-Episode Psychosis in Women: Which Antipsychotic Is the Preferred Choice?
Second-Generation Antipsychotics for OCD Augmentation
Faculty: Robert Hudak, M.D. Host: Flavio Guzmán, M.D. Learn more about our memberships here Earn 1.25 CME: Treatment-Resistant OCD: From SSRIs to Augmentation Second-Generation Antipsychotics for OCD …
Notas del episodio
Faculty: Robert Hudak, M.D. Host: Flavio Guzmán, M.D.
Are Z-Drugs Safe in the First Trimester of Pregnancy?
In this episode, we review a JAMA Psychiatry study of over 4 million pregnancies examining first-trimester Z-drug exposure and congenital malformations. Dr. Amanda Koire explains why overall risk wasn't …
Notas del episodio
In this episode, we review a JAMA Psychiatry study of over 4 million pregnancies examining first-trimester Z-drug exposure and congenital malformations. Dr. Amanda Koire explains why overall risk wasn't increased, what the neural tube defect signal means, and how to evaluate insomnia before prescribing.
Faculty: Amanda Koire, M.D., Ph.D. Host: Flavio Guzmán, M.D.
Glutamatergic Augmentation in OCD
Faculty: Robert Hudak, M.D. Host: Flavio Guzmán, M.D. Learn more about our memberships here Earn 1.25 CME: Treatment-Resistant OCD: From SSRIs to Augmentation Glutamatergic Augmentation in OCD: Memantine …
Notas del episodio
Faculty: Robert Hudak, M.D. Host: Flavio Guzmán, M.D.
Schizophrenia: Which of Seven Antipsychotics Wins?
Faculty: Oliver Freudenreich, M.D. Host: Flavio Guzmán, M.D. Learn more about our memberships here Earn 0.75 CMEs: Quick Take Vol. 85 Schizophrenia: Which of Seven Antipsychotics Wins on Acute Efficacy and Safety?
SSRI Dosing for OCD: Beyond FDA Guidelines
Faculty: Robert Hudak, M.D. Host: Flavio Guzmán, M.D. Learn more about our memberships here Earn 1.25 CME: SSRI Dosing for OCD: Beyond FDA Guidelines Treatment-Resistant OCD: From SSRIs to Augmentation
Trazodone for Insomnia and Comorbid Depression
In this episode, we explore a new meta-analysis reconciling trazodone's real-world reputation with cautious sleep medicine guidelines, examining its effects on sleep architecture and depressive symptoms in …
Notas del episodio
In this episode, we explore a new meta-analysis reconciling trazodone's real-world reputation with cautious sleep medicine guidelines, examining its effects on sleep architecture and depressive symptoms in patients with comorbid insomnia and depression, alongside its notable side effect profile. Can a decades-old antidepressant be the missing link for restorative sleep?
Faculty: Paul Zarkowski, M.D. Host: Flavio Guzmán, M.D.
Antipsychotics, Prolactin, and Sexual Side Effects
In this episode, we explore why antipsychotics cause hyperprolactinemia and sexual side effects, a leading reason patients quietly stop treatment. Dr. Oliver Freudenreich breaks down which medications carry the …
Notas del episodio
In this episode, we explore why antipsychotics cause hyperprolactinemia and sexual side effects, a leading reason patients quietly stop treatment. Dr. Oliver Freudenreich breaks down which medications carry the highest risk, the long-term health implications, and practical strategies for monitoring, switching, or augmenting therapy.
Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D.
EMERGENT-5: Cobenfy and Treatment Durability
In this episode, we sit down with Dr. Oliver Freudenreich to unpack EMERGENT-5, the year-long trial tracking Cobenfy's real-world durability and safety in schizophrenia. We explore whether early symptom gains …
Notas del episodio
In this episode, we sit down with Dr. Oliver Freudenreich to unpack EMERGENT-5, the year-long trial tracking Cobenfy's real-world durability and safety in schizophrenia. We explore whether early symptom gains hold up over time, what side effects persist, and why blood pressure monitoring now deserves a permanent spot on your checklist.
Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D.
Antipsychotics and Weight Gain
In this episode, we sit down with Dr. Oliver Freudenreich to unpack antipsychotic-induced weight gain — why it happens, which medications carry the highest risk, and how to build a proactive ABC strategy using …
Notas del episodio
In this episode, we sit down with Dr. Oliver Freudenreich to unpack antipsychotic-induced weight gain — why it happens, which medications carry the highest risk, and how to build a proactive ABC strategy using switching, metformin, and emerging GLP-1 agonists to protect your patients' metabolic health.
Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D.
EPA vs. DHA: Fish Oil and Treatment-Resistant Depression
In this episode, we explore whether EPA, a specific omega-3 fatty acid, can help patients with treatment-resistant depression. Dr. Derick Vergne breaks down the clinical evidence, dosing, and the …
Notas del episodio
In this episode, we explore whether EPA, a specific omega-3 fatty acid, can help patients with treatment-resistant depression. Dr. Derick Vergne breaks down the clinical evidence, dosing, and the anti-inflammatory mechanisms that may explain why EPA outperforms DHA in easing stubborn depressive symptoms.
Faculty: Derick E. Vergne, M.D. Host: Richard Seeber, M.D.
AUD Medications and Hepatic Safety
In this episode, we explore how liver status shapes medication choice for alcohol use disorder. Dr. Kevin Sevarino breaks down a practical algorithm for selecting between naltrexone, acamprosate, disulfiram …
Notas del episodio
In this episode, we explore how liver status shapes medication choice for alcohol use disorder. Dr. Kevin Sevarino breaks down a practical algorithm for selecting between naltrexone, acamprosate, disulfiram, and other options, tailored to hepatic function, from early liver disease through decompensated cirrhosis.
Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Richard Seeber, M.D.
GLP-1 Agonists in Serious Mental Illness: Current Evidence
In this episode, we explore whether GLP-1 agonists like semaglutide can tackle the metabolic toll of antipsychotics in schizophrenia. Can a drug famous for celebrity weight loss actually protect our most …
Notas del episodio
In this episode, we explore whether GLP-1 agonists like semaglutide can tackle the metabolic toll of antipsychotics in schizophrenia. Can a drug famous for celebrity weight loss actually protect our most vulnerable psychiatric patients from diabetes and obesity before the damage is done?
Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D.
Gabapentin, Topiramate & Baclofen in AUD
In this episode, we explore three off-label but evidence-supported medications — gabapentin, topiramate, and baclofen — for alcohol use disorder, examining their mechanisms, dosing strategies, tolerability …
Notas del episodio
In this episode, we explore three off-label but evidence-supported medications — gabapentin, topiramate, and baclofen — for alcohol use disorder, examining their mechanisms, dosing strategies, tolerability challenges, and which patients are most likely to benefit when first-line treatments have failed.
Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Richard Seeber, M.D.
Deprescribing Benzodiazepines: When Tapering Might Do More Harm Than Good
In this episode, we explore the nuanced landscape of benzodiazepine tapering, guided by a major 2024 joint clinical practice guideline. Are we training a generation of psychiatrists too afraid to prescribe one …
Notas del episodio
In this episode, we explore the nuanced landscape of benzodiazepine tapering, guided by a major 2024 joint clinical practice guideline. Are we training a generation of psychiatrists too afraid to prescribe one of psychiatry's most effective drug classes? Dr. Scott Beach unpacks the risks, benefits, and clinical realities.
Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.
Disulfiram Unpacked: Efficacy, Risks, and Liver Safety
In this episode, we explore disulfiram (Antabuse), one of the oldest FDA-approved treatments for alcohol use disorder. Dr. Kevin Sevarino breaks down its mechanism, efficacy data, and critical hepatic safety …
Notas del episodio
In this episode, we explore disulfiram (Antabuse), one of the oldest FDA-approved treatments for alcohol use disorder. Dr. Kevin Sevarino breaks down its mechanism, efficacy data, and critical hepatic safety considerations. Could enforced sobriety be the missing piece for your most treatment-resistant patients?
Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Richard Seeber, M.D.
GLP-1s and Lithium: What Clinicians Need to Know
In this episode, we explore a surprising drug interaction that every lithium-prescribing clinician should know about: can semaglutide, the widely used GLP-1 receptor agonist, push lithium levels into toxic …
Notas del episodio
In this episode, we explore a surprising drug interaction that every lithium-prescribing clinician should know about: can semaglutide, the widely used GLP-1 receptor agonist, push lithium levels into toxic territory — and if so, why?
Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D.
Naltrexone for Alcohol Use Disorder: What You Should Know
In this episode, we explore how naltrexone — the most widely used medication for alcohol use disorder in the US — works, how to dose it safely, and why liver disease may not be the barrier you think it is. Can …
Notas del episodio
In this episode, we explore how naltrexone — the most widely used medication for alcohol use disorder in the US — works, how to dose it safely, and why liver disease may not be the barrier you think it is. Can a medication that doesn't target abstinence still be a game-changer for your patients?
Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D Host: Richard Seeber, M.D.
The OPTIMUM Trial: A Roadmap for Treatment-Resistant Depression in Late Life
In this episode, we explore the OPTIMUM trial, a landmark study examining how to treat older adults with treatment-resistant depression when antidepressants fall short. When adding a medication outperforms …
Notas del episodio
In this episode, we explore the OPTIMUM trial, a landmark study examining how to treat older adults with treatment-resistant depression when antidepressants fall short. When adding a medication outperforms switching entirely — and what that means for the patient sitting across from you — the answer may reshape your clinical approach.
Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.
Difficult-to-Treat Depression: First, Second, and Third-Line Strategies
In this episode, we explore what to do when antidepressants aren't working. How do you systematically approach a patient who isn't getting better — and when do you switch versus augment? Dr. Sagar Parikh walks …
Notas del episodio
In this episode, we explore what to do when antidepressants aren't working. How do you systematically approach a patient who isn't getting better — and when do you switch versus augment? Dr. Sagar Parikh walks through CANMAT's evidence-based framework for difficult-to-treat depression.
Faculty: Sagar V. Parikh, M.D., F.R.C.P.C. Host: Richard Seeber, M.D.
Is High-Dose Olanzapine A Clozapine Alternative?
In this episode, we explore whether high-dose olanzapine — beyond the FDA-approved 20 mg ceiling — can be a viable strategy for patients with treatment-resistant schizophrenia when clozapine isn't yet an …
Notas del episodio
In this episode, we explore whether high-dose olanzapine — beyond the FDA-approved 20 mg ceiling — can be a viable strategy for patients with treatment-resistant schizophrenia when clozapine isn't yet an option. Can pushing the dose bridge the gap between partial response and full remission?
Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.
CANMAT Guidelines: Herbs, Supplements, and Depression
In this episode, we explore what the CANMAT guidelines say about complementary and alternative medicine (CAM) for depression — from St. John's wort to saffron — and how to have evidence-based, collaborative …
Notas del episodio
In this episode, we explore what the CANMAT guidelines say about complementary and alternative medicine (CAM) for depression — from St. John's wort to saffron — and how to have evidence-based, collaborative conversations with patients who prefer a more natural approach to treatment.
Faculty: Sagar V. Parikh, M.D., F.R.C.P.C. Host: Richard Seeber, M.D.
Xylazine in the ED: Managing Toxicity
In this episode, we explore the growing threat of xylazine — a veterinary sedative increasingly found in illicit drug supplies — and what clinicians need to know when naloxone simply isn't enough. Dr. David …
Notas del episodio
In this episode, we explore the growing threat of xylazine — a veterinary sedative increasingly found in illicit drug supplies — and what clinicians need to know when naloxone simply isn't enough. Dr. David Gorelick breaks down the current evidence on diagnosis, treatment, and the critical gaps that remain.
Faculty: David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M. Host: Richard Seeber, M.D.
Choosing the First Step in Depression Treatment: A CANMAT Guide
In this episode, we explore how to select the right initial treatment for depression using the updated CANMAT guidelines. How do severity, patient preference, and treatment availability shape your first …
Notas del episodio
In this episode, we explore how to select the right initial treatment for depression using the updated CANMAT guidelines. How do severity, patient preference, and treatment availability shape your first clinical move? Dr. Sagar Parikh breaks down the evidence on psychotherapy, antidepressants, and when to combine both.
Faculty: Sagar V. Parikh, M.D. Host: Richard Seeber, M.D.
After Delirium Clears: When to Deprescribe?
In this episode, we explore the hidden dangers of leaving antipsychotics running long after a hospital delirium episode has resolved. Could a medication prescribed to keep your patient safe in the short term …
Notas del episodio
In this episode, we explore the hidden dangers of leaving antipsychotics running long after a hospital delirium episode has resolved. Could a medication prescribed to keep your patient safe in the short term actually be harming them months later — and what does the latest evidence say about stopping it?
Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.
The Clinician's Guide to Paliperidone & Risperidone LAIs
In this episode, we explore the practical dosing, initiation, and conversion strategies for paliperidone palmitate and risperidone long-acting injectables in schizophrenia. How do you manage a missed six-month …
Notas del episodio
In this episode, we explore the practical dosing, initiation, and conversion strategies for paliperidone palmitate and risperidone long-acting injectables in schizophrenia. How do you manage a missed six-month injection — reload or continue? Dr. Brian Miller breaks down everything you need to know to prescribe these formulations with confidence.
Faculty: Brian Miller, M.D., Ph.D., M.P.H. Host: Richard Seeber, M.D.
Antipsychotic Switching: Six Clinical Tips
In this episode, we explore the surprisingly thin evidence base behind antipsychotic switching — one of psychiatry's most common clinical maneuvers. Dr. Oliver Freudenreich breaks down a landmark systematic …
Notas del episodio
In this episode, we explore the surprisingly thin evidence base behind antipsychotic switching — one of psychiatry's most common clinical maneuvers. Dr. Oliver Freudenreich breaks down a landmark systematic review and shares six practical tips to help clinicians switch antipsychotics safely and confidently.
Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.
Aquí están los 40 episodios más recientes de 100. Los anteriores están en el feed del podcast.
Podcasts similares
Más podcasts de Salud y forma física
¿Es tu podcast?
Confírmalo con una entrada en tu feed: aquí recibes un código, lo añades como podcast:txt en el canal de tu feed y nosotros lo comprobamos. Después tu podcast aparecerá como «verificado» en SoundNode.